Jennifer Vicente
Adult Health · Long Beach, CANPI 1235522483
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,987, 4.0 times the $492 reported in 2021. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $32.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Pfizer$342
- Novo Nordisk$303
- AbbVie$301
- Otsuka America Pharmaceutical, Inc.$275
- plus $2K from 29 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$5,922100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $1,382 |
| Lilly USA, LLC | 29 | $1,044 |
| Pfizer | 21 | $342 |
| Novo Nordisk | 11 | $303 |
| AbbVie | 15 | $301 |
| Otsuka America Pharmaceutical, Inc. | 8 | $275 |
| Bayer | 9 | $243 |
| Exact Sciences | 4 | $185 |
| Astellas Pharma US Inc | 4 | $183 |
| GSK | 8 | $175 |
| Dexcom, Inc. | 4 | $165 |
| Johnson & Johnson | 1 | $141 |
| Phathom Pharmaceuticals, Inc. | 1 | $120 |
| Viiv Healthcare Company | 4 | $111 |
| Antares Pharma, Inc. | 5 | $105 |
| Merck | 5 | $105 |
| Gilead | 5 | $99 |
| Dompe US, Inc. | 1 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $77 |
| Bausch Health US, LLC | 3 | $70 |
| Abbott | 2 | $58 |
| Neurocrine Biosciences, Inc. | 1 | $55 |
| Halozyme Inc | 2 | $50 |
| Verity Pharmaceuticals Inc. | 1 | $36 |
| Lundbeck LLC | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Alfasigma USA, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,928 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $24,831 |
| FarxigaDapagliflozin Propanediol | 15 | $11,445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $490 |
| Bupropion XlBupropion Hcl | 12 | $360 |
| Fluticasone Propionate | 32 | $354 |
| Atorvastatin Calcium | 28 | $339 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $306 |
| Simvastatin | 16 | $250 |
| Levothyroxine Sodium | 24 | $243 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $208 |
| Rosuvastatin Calcium | 16 | $204 |
| Omeprazole | 17 | $174 |
| Ciprofloxacin Hcl | 42 | $166 |
| Alendronate Sodium | 14 | $160 |
| Azithromycin | 41 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,044 | $24,83124 claims |
| AstraZenecaFarxiga | $1,382 | $11,44515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Long Beach
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.